Tech Company Financing Transactions
Actinium Pharmaceuticals Funding Round
Actinium Pharmaceuticals secured a $5.1 million funding round on 12/28/2012. Backers included private investors.
Transaction Overview
Company Name
Announced On
12/28/2012
Transaction Type
Venture Equity
Amount
$5,100,000
Round
Undisclosed
Investors
Proceeds Purpose
Funding will be used primarily for further development of Actimab-A, Actinium's lead drug candidate in multicenter Phase I/II trials in Acute Myeloid Leukemia (AML) and Iomab -- B, a Phase II clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 Madison Ave. 7th Floor
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Undisclosed
Website
Email Address
Overview
ATNM develops innovative alpha particle immunotherapeutics for the therapeutic utilization of radiopharmaceuticals with monoclonal antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sandesh Seth
Chief Medical Officer
Mark Berger
Chief Scientific Officer
Dale Ludwig
Vice President
Vijay Reddy
VP - Bus. Development
Anil Kapur
VP - Operations
Cynthia Pussinen
VP - Regulatory Affairs
Mamata Gokhale
VP - Regulatory Affairs
David Gould
Browse more venture capital transactions:
Prev: 12/28/2012: NanoMedical Systems venture capital transaction
Next: 12/28/2012: ThruPoint venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs